Ind-Swift Limited (INDSWFTLTD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ind-Swift Limited (INDSWFTLTD) has a cash flow conversion efficiency ratio of -0.039x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs158.56 Million ≈ $1.71 Million USD) by net assets (Rs-4.02 Billion ≈ $-43.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ind-Swift Limited to measure how much of total assets are equity-financed.
Ind-Swift Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Ind-Swift Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INDSWFTLTD cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Ind-Swift Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ind-Swift Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Moksh Ornaments Limited
NSE:MOKSH
|
-0.121x |
|
Magmatic Resources Ltd
AU:MAG
|
-0.148x |
|
PT Dafam Property Indonesia Tbk
JK:DFAM
|
1.537x |
|
Pioneer Lithium Ltd
AU:PLN
|
N/A |
|
Citatah Tbk
JK:CTTH
|
-0.063x |
|
EBANG INTL HLDGS (NEW) A
F:7EBA
|
N/A |
|
Standard Uranium Ltd.
V:STND
|
-0.056x |
|
Venzee Technologies Inc
V:VENZ
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Ind-Swift Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Ind-Swift Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ind-Swift Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs-4.02 Billion ≈ $-43.51 Million |
Rs158.56 Million ≈ $1.71 Million |
-0.039x | -78.15% |
| 2024-03-31 | Rs-6.91 Billion ≈ $-74.71 Million |
Rs152.83 Million ≈ $1.65 Million |
-0.022x | +78.66% |
| 2023-03-31 | Rs-7.05 Billion ≈ $-76.21 Million |
Rs730.46 Million ≈ $7.90 Million |
-0.104x | -48.73% |
| 2022-03-31 | Rs-7.20 Billion ≈ $-77.90 Million |
Rs502.02 Million ≈ $5.43 Million |
-0.070x | +41.76% |
| 2021-03-31 | Rs-6.95 Billion ≈ $-75.18 Million |
Rs831.93 Million ≈ $9.00 Million |
-0.120x | -146.68% |
| 2020-03-31 | Rs-7.13 Billion ≈ $-77.12 Million |
Rs345.96 Million ≈ $3.74 Million |
-0.049x | +23.32% |
| 2019-03-31 | Rs-6.76 Billion ≈ $-73.14 Million |
Rs427.86 Million ≈ $4.63 Million |
-0.063x | -485.49% |
| 2018-03-31 | Rs-6.63 Billion ≈ $-71.72 Million |
Rs71.66 Million ≈ $774.98K |
-0.011x | -486.50% |
| 2017-03-31 | Rs-6.16 Billion ≈ $-66.56 Million |
Rs-17.21 Million ≈ $-186.10K |
0.003x | -99.43% |
| 2016-03-31 | Rs-2.45 Billion ≈ $-26.54 Million |
Rs-1.19 Billion ≈ $-12.92 Million |
0.487x | +122.46% |
| 2015-03-31 | Rs-395.00 Million ≈ $-4.27 Million |
Rs855.75 Million ≈ $9.25 Million |
-2.166x | -328.56% |
| 2014-03-31 | Rs1.08 Billion ≈ $11.72 Million |
Rs1.03 Billion ≈ $11.11 Million |
0.948x | +240.79% |
| 2013-03-31 | Rs2.17 Billion ≈ $23.50 Million |
Rs-1.46 Billion ≈ $-15.82 Million |
-0.673x | -470.93% |
| 2011-03-31 | Rs3.30 Billion ≈ $35.67 Million |
Rs598.64 Million ≈ $6.47 Million |
0.182x | +9122.60% |
| 2010-03-31 | Rs2.80 Billion ≈ $30.26 Million |
Rs-5.63 Million ≈ $-60.88K |
-0.002x | -100.95% |
| 2009-03-31 | Rs2.42 Billion ≈ $26.12 Million |
Rs509.22 Million ≈ $5.51 Million |
0.211x | +76.03% |
| 2008-03-31 | Rs1.78 Billion ≈ $19.27 Million |
Rs213.43 Million ≈ $2.31 Million |
0.120x | +316.53% |
| 2007-03-31 | Rs1.49 Billion ≈ $16.09 Million |
Rs-82.28 Million ≈ $-889.78K |
-0.055x | -206.94% |
| 2006-03-31 | Rs1.30 Billion ≈ $14.03 Million |
Rs67.09 Million ≈ $725.56K |
0.052x | -- |
About Ind-Swift Limited
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin… Read more